- 2025,09,15
Recently, the Eicosapentaenoic Acid Ethyl Ester Soft Capsules ("EPA Soft Capsules"), developed by Zhejiang Cheng Yi Pharmaceutical Co., Ltd., has officially obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA). This marks the smooth implementation of Cheng Yi Pharmaceutical's layout in the field of high-purity EPA preparations.
Since submitting the registration application on July 20, 2023, Cheng Yi Pharmaceutical's EPA Soft Capsules have been approved under the Category 4 of chemical drugs. They are used to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL). When used in combination with statins, this drug can be used for adult patients diagnosed with cardiovascular disease or diabetes mellitus accompanied by ≥2 other cardiovascular disease risk factors and complicated with hypertriglyceridemia (≥150 mg/dL) to reduce the risk of cardiovascular events.
It is reported that there are currently 6 manufacturers whose Eicosapentaenoic Acid Ethyl Ester Soft Capsules have been approved by the NMPA. With the successful approval of this fish oil product, relying on its integrated advantages of API (Active Pharmaceutical Ingredient) and preparation in the field of high-purity EPA, Cheng Yi Pharmaceutical is expected to develop this product into another core growth driver following its joint-related drugs. This will further enrich the drug options for lipid regulators in China, help the company compete in the 20-billion-yuan market of lipid-lowering drugs, and become a new growth point for Dongtou's marine economy.
Source: Dongtou Release